Immuneering CEO interviewed by Alex Keown of BioSpace, Inc

Published: Jan 28, 2020

 

By Alex Keown

 

In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though. What may be more effective in the long run, is hitting a disease along multiple target lines. That’s the idea at Cambridge, Mass.-based Immuneering.